Genprex to Present at Upcoming H.C. Wainwright Conference
LOS ANGELES, CA - (NewMediaWire) - September 08, 2023 - (InvestorBrandNetwork via NewMediaWire) - IBN, a multifaceted financial news, content creation and publishing company, is utilized by both public and private companies to optimize investor awareness and recognition.
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its CFO Ryan Confer will be providing an overview of the company's pioneering gene therapies for cancer and diabetes at the upcoming H.C. Wainwright 25th Annual Global Investment Conference. Confer's presentation is scheduled to begin at 3:00 p.m. ET on Wednesday, Sep. 13, 2023. Interested parties should visit https://ibn.fm/vvilS to register and access the presentation. A recording will be available for replay on Genprex's website for a period of time. In addition, as detailed in the announcement, Confer will be available for one-on-one meetings with investors through the conference platform.
To view the full press release, visit https://ibn.fm/VWFM6
About Genprex Inc.
Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral ONCOPREX(R) Nanoparticle Delivery System, which encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The company's lead product candidate, REQORSA(R) (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer ("NSCLC") and small cell lung cancer ("SCLC"). Each of Genprex's three lung cancer clinical programs has received a Fast Track Designation from the Food and Drug Administration ("FDA"), and its SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an adeno-associated virus ("AAV") vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-003 for type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. For more information, visit the company's website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company's newsroom at http://ibn.fm/GNPX
About IBN
IBN has introduced 50+ distinct investor-focused brands over the last 15+ years and has leveraged these unique brands to amass a collective audience of millions of social media followers. In conjunction with 5,000+ syndication partnerships, IBN's broad-based investor-facing brands help fulfill the diverse demands and needs of our rapidly growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, harnessing the energy and experience of our team of specialized experts to exceed the expectations of each of our client-partners.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
